scholarly journals L'immunodiagnostic de la fasciolose à Fasciola gigantica par la technique ELISA au Sénégal. Observatoins préliminaires chez deux agneaux

1994 ◽  
Vol 47 (3) ◽  
pp. 291-294
Author(s):  
O.T. Diaw ◽  
M.M. Sèye ◽  
M. Seye ◽  
Y. Sarr ◽  
Georges Vassiliades
Keyword(s):  
Fasciola Gigantica ◽  
Test Elisa

L'objet de ce travail est de tester l'utilisation de la technique ELISA au Sénégal pour le diagnostic de la fasciolose à Fasciola gigantica chez le mouton en utilisant comme antigène les produits métaboliques d'excrétion-sécrétion du parasite. Alors que les analyses coprologiques classiques sont négatives jusqu'à la 14è semaine, l'analyse immunologique par le test ELISA permet de trouver les premiers anticorps anti-Fasciola gigantica dès la 4è semaine après l'infection.

scholarly journals Diagnostic sérologique de la fasciolose bovine à Fasciola gigantica par un test Elisa en Mauritanie

2003 ◽  
Vol 56 (3-4) ◽  
pp. 135 ◽  
Author(s):  
A. Bent Mohamed ◽  
D. Cheikh ◽  
E. Thiam ◽  
Philippe Jacquiet
Keyword(s):  
Fasciola Gigantica ◽  
Test Elisa ◽  
Schistosoma Bovis

Depuis la mise en eau des barrages de Diama et de Manantali sur le fleuve Sénégal, les trématodoses du bétail, dont la fasciolose à Fasciola gigantica, ont connu une recrudescence importante. Un test de dépistage sérologique par Elisa qui utilise comme antigène les produits d’excrétion-sécrétion des douves adultes a été développé. Les résultats de ce test ont été comparés à la recherche directe de douves adultes dans les canaux biliaires chez 176 bovins abattus dans la basse vallée du fleuve. Parmi les 40 bovins porteurs de douves adultes, 39 ont été positifs en Elisa. Par ailleurs, 24 bovins ont présenté des titres en anticorps élevés sans douves adultes dans leurs canaux biliaires. Pour 22 de ces 24 animaux, l’abattage a eu lieu entre mars et juillet, période pendant laquelle les bovins s’infestent, suggérant ainsi que l’essentiel des cas de discordance entre le diagnostic par Elisa et la recherche de douves adultes provenait d’un dépistage précoce de l’infestation par la méthode Elisa. La plupart des animaux présentant une infestation monospécifique par d’autres trématodes (Schistosoma bovis ou paramphistomes) n’ont pas eu d’anticorps anti-F. gigantica. Le suivi sérologique et coproscopique d’une cohorte de veaux soumis à une infestation naturelle à proximité du fleuve Sénégal a permis de confirmer que la période d’infestation a lieu de mars à juillet. De plus, une enquête transversale sur 15 troupeaux de bovins de la basse vallée du fleuve a permis de montrer que les deux tiers de ces troupeaux étaient infestés avec des prévalences sérologiques variant de 13 à 33 p. 100

scholarly journals A Study of Varicella Seroprevalence in a Pediatric and Adolescent Population in Florence (Italy). Natural Infection and Vaccination-Acquired Immunization

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 152
Author(s):  
Beatrice Zanella ◽  
Angela Bechini ◽  
Benedetta Bonito ◽  
Marco Del Riccio ◽  
Alessandra Ninci ◽  
...  
Keyword(s):  
Natural Infection ◽  
Age Groups ◽  
Varicella Vaccination ◽  
Age Group ◽  
Disease Notification ◽  
Test Elisa ◽  
Vaccine Schedule ◽  
Almost All ◽  
Vaccination Campaigns ◽  
Dose Vaccine

Background: Varicella is a well-known infectious disease that can have severe complications, also in young children. The Universal Varicella Vaccination (UVV) program was introduced in Tuscany (Italy) in 2003, with a two-dose vaccine schedule given to children between their 13th and 15th month, and at 5–6 years old, as a monovalent for varicella (V) or tetravalent (measles, mumps, rubella and varicella (MMRV)) formulation. Although varicella notifications have dramatically fallen in the last two decades, varicella disease underreporting remains a challenge. Methods: A qualitative immunoenzymatic test (ELISA) was used to measure the presence of anti-varicella antibodies in 165 sera of subjects aged 1–18 years residing in the province of Florence (Italy). Information regarding the anamnestic and vaccination status (including disease notification) was also collected. Results: Our study showed an overall varicella seropositivity of 75.8% (reaching the maximum at 96.3% in the 15–18 years age group). We found that varicella disease notification had been recorded for only 7/165 subjects; however, since 42/165 recalled having had the disease, we can hypothesize that some of them must have been underreported. Furthermore, our study showed that the presence of antibodies after the varicella vaccination remained over time, lasting up to 12 years. Conclusions: Although varicella seroprevalence is <95% in almost all our age groups (except for the 15–18 years age group), our data are encouraging and reflect the success of the introduction of the UVV program and the vaccination campaigns promoted in the Tuscany region.

scholarly journals SAT0032 INCIDENCE OF RHEUMATOID ARTHRITIS IN PATIENTS WITH NEW ONSET OF MUSCULOSKELETAL SYMPTOMS AND ANTI-CPP POSITIVITY COMPARED TO ANTI-CPP NEGATIVE PATIENTS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 946.1-946
Author(s):  
S. Dauth ◽  
M. Köhm ◽  
T. Oberwahrenbrock ◽  
U. Henkemeier ◽  
T. Rossmanith ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Point Of Care ◽  
Early Arthritis ◽  
Clinical Parameters ◽  
Research Support ◽  
Point Of Care Test ◽  
Test Elisa ◽  
Patient Reported ◽  
New Onset

Background:Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease. Strategies for its early detection and diagnosis are of high importance as prompt treatment improves clinical and structural outcome. Autoantibodies against cyclic citrullinated proteins (anti-CCP) have been associated with RA-development. Non-specific musculoskeletal (nsMSK) symptoms are often described prior to RA development. Majority of patients with nsMSK symptoms present to their general practice (GP) first. Studies of early arthritis cohorts have shown that many early arthritis patients cannot be accurately diagnosed at their first visit and are often referred as undifferentiated arthritis patients.Objectives:To evaluate the incidence of anti-CCP positivity in patients with new onset of nsMSK symptoms and the incidence of RA in these patients over a 3-year follow-up period compared to anti-CPP negative patients.Methods:In this prospective study (PANORA), 978 patients with new onset of nsMSK symptoms were included in 77 GP sites in Germany. Patients with a positive anti-CCP rapid-test (CCPoint®) were referred to Rheumatology Department (RD) for rheumatological assessment, RA-evaluation and an anti-CCP validation test (ELISA). ELISA anti-CCP positive patients without RA were monitored every 6 months for a total follow-up of 36 months or until RA-diagnosis. Patients with a negative anti-CPP result (CCPoint® or ELISA) are followed up with a questionnaire after 1 and 3 y.Results:From 978 included patients, 105 (10.7%) were CCPoint® positive. 96 were tested with ELISA and 27 (28.1%) were confirmed anti-CCP positive. 9 (33.3%) were diagnosed with RA at the first RD visit (study visit 2); 4 further patients were diagnosed with RA during the follow-up (FU) period so far. Overall, 48.1% of ELISA-positive (ELISA+) patients were diagnosed with RA up to now; 11 ELISA+ patients are still in the FU period of the study. Of the 868 CCPoint® negative patients, currently, 282 have filled out a 1-year FU questionnaire; 3.5% of those reported a RA diagnosis (Table 1). As expected, clinical parameters at V2 (e.g. CRP, swollen and tender joint count) were worse in the ELISA+/RA+ group compared to the ELISA-/RA- group, but no obvious differences were detected between ELISA+ patients who were diagnosed with RA during the FU period (after V2) and ELISA-/RA- patientsTable 1.Number and percentage of patients with a RA diagnosisAnti-CCP statusVisit 2Follow-up*TotalPoint-of-Care Test --3.5% (10 of 282)#3.5% (10 of 282)#Point-of-Care Test + / ELISA -2.9% (2 of 69)0% (0 of 34)#2.9% (2 of 69)Point-of-Care Test + / ELISA +33.3% (9 of 27)14.8% (4 of 27)48.1% (13 of 27)$* 1 year-questionnaire for Point-of-Care Test and ELISA negative patients or every 6 months follow-up for ELISA positive patients;#Patient-reported;$11 patients are still in the follow-up phase of the studyConclusion:Currently, 48.1% of anti-CCP+ (ELISA) patients have received a RA diagnosis, whereas 3.5% of the anti-CCP- (CCPoint®) received a RA diagnosis (patient reported), which underlines, that anti-CCP can be used as a marker to identify high-risk patients in GP setting. While clinical parameters are correlated with the diagnosis of RA, they are not suited for predicting future RA development alone. Anti-CCP, possibly in combination with additional parameters imaging, might increase the likelihood to early diagnose or predict RA development.Figure 1.Study overview: Patient distribution depending on anti-CCP results and RA diagnosis.Disclosure of Interests:Stephanie Dauth Grant/research support from: BMS, Michaela Köhm Grant/research support from: Pfizer, Janssen, BMS, LEO, Consultant of: BMS, Pfizer, Speakers bureau: Pfizer, BMS, Janssen, Novartis, Timm Oberwahrenbrock Grant/research support from: BMS, Ulf Henkemeier: None declared, Tanja Rossmanith Grant/research support from: Janssen, BMS, LEO, Pfizer, Karola Mergenthal Grant/research support from: BMS, Juliana J. Petersen Grant/research support from: BMS, Harald Burkhardt Grant/research support from: Pfizer, Roche, Abbvie, Consultant of: Sanofi, Pfizer, Roche, Abbvie, Boehringer Ingelheim, UCB, Eli Lilly, Chugai, Bristol Myer Scripps, Janssen, and Novartis, Speakers bureau: Sanofi, Pfizer, Roche, Abbvie, Boehringer Ingelheim, UCB, Eli Lilly, Chugai, Bristol Myer Scripps, Janssen, and Novartis, Frank Behrens Grant/research support from: Pfizer, Janssen, Chugai, Celgene, Lilly and Roche, Consultant of: Pfizer, AbbVie, Sanofi, Lilly, Novartis, Genzyme, Boehringer, Janssen, MSD, Celgene, Roche and Chugai

scholarly journals Fasciola gigantica cathepsin L proteinase-based synthetic peptide for immunodiagnosis and prevention of sheep fasciolosis

Biopolymers ◽  
2007 ◽  
Vol 90 (3) ◽  
pp. 349-357 ◽  
Author(s):  
Jan Jezek ◽  
Rashika El Ridi ◽  
Mohamed Salah ◽  
Amal Wagih ◽  
Haidy W. Aziz ◽  
...  
Keyword(s):  
Synthetic Peptide ◽  
Cathepsin L ◽  
Fasciola Gigantica

Efficient inhibition of cathepsin B by a secreted type 1 cystatin of Fasciola gigantica

2012 ◽  
Vol 186 (2) ◽  
pp. 126-133 ◽  
Author(s):  
Sinee Siricoon ◽  
Suksiri Vichasri Grams ◽  
Rudi Grams
Keyword(s):  
Cathepsin B ◽  
Fasciola Gigantica

scholarly journals Determination du niveau d'anticorps antitetaniques en donneurs de sang au moyen du test ELISA-TÉTANOS (São Paulo, SP, Bresil)

1990 ◽  
Vol 32 (6) ◽  
pp. 461-466
Author(s):  
Luzia Cristina Contim Ferrato ◽  
Adelaide José Vaz ◽  
Eide Dias Camargo ◽  
Ana Maria Carvalho de Souza
Keyword(s):  
Sao Paulo ◽  
São Paulo ◽  
Test Elisa ◽  
Protection Contre

Le test ELISA-TÉTANOS (Biosys, France) a été utilisé pour le titrage des anti-corps tétaniques (sensibilité = 0,0025 UI/ml) en sérums humains de donneurs de sang, 566 hommes et 108 femmes, âges de 18 à 58 ans, moyenne de 29 ans, provenant de São Paulo, SP, Brésil. L'OMS, acceptant seulement la séroneutralisation sur souris (NT), la méthode de référence, pour les études sur la protection contre le tétanos, préconise le titre de 0,01 UI/ml comme minimum protecteur. BOURLEAUD & HUET ont proposé la limite de 0,06 UI/ml quand s'emploie le test ELISA, en attendant à une certaine discordance inévitable entre les méthodes. Parmi les 674 sérums étudiés, 178 (26,41%) n'ont pas présenté d'anticorps (< 0,0025 UI/ml); 413 (61,28%) ont présenté des résultats égaux ou supérieurs à 0,01 UI/ml et en 232 (34,42%) les titres ont été égaux ou supérieurs à 0,06 UI/ml. Le pourcentage d'individus protégés a été inversement proportionnel à 1'âge: environ 50% dans le groupe le plus jeune (hommes de 18 à 35 ans et femmes de 18 à 23 ans) contre environ 10% dans le groupe de plus de 42 ans ont présenté des titres sûrement protecteurs (> 0,06 UI/ml).

The prevalence and economic significance of Fasciola gigantica and Stilesia hepatica in slaughtered animals in the semi-arid coastal Kenya

2006 ◽  
Vol 38 (6) ◽  
pp. 475-483 ◽  
Author(s):  
E. O. Mungube ◽  
S. M. Bauni ◽  
B.-A. Tenhagen ◽  
L. W. Wamae ◽  
J. M. Nginyi ◽  
...  
Keyword(s):  
Fasciola Gigantica ◽  
Economic Significance ◽  
Coastal Kenya ◽  
Semi Arid
Sign in / Sign up

Export Citation Format

Share Document